Impact of Treatment Approaches on Mortality in Cancer Patients With Non-ST Elevation Myocardial Infarction: Invasive vs. Conservative Strategies
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 12,500
- Locations
- 1
- Primary Endpoint
- hospital mortality
Study Overview
Brief Summary
This retrospective study investigates the impact of invasive versus conservative management strategies in cancer patients presenting with non-ST elevation myocardial infarction (non-ST MI). Patients aged 18 and older, who were treated for non-ST MI in a hospital setting and had a confirmed cancer diagnosis, are included. The primary outcome is hospital mortality, assessed using GRACE scores to evaluate mortality risk. Patients are grouped based on their received interventions-either invasive (including coronary angiography and revascularization) or pharmacological treatment. Risk factors contributing to mortality, such as cancer type, metastasis presence, comorbidities, and laboratory findings, will also be analyzed to better understand the interplay of oncologic and cardiovascular conditions in this population.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Retrospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Age: Patients aged 18 years and older.
- •Diagnosis: Patients with a confirmed cancer diagnosis.
- •Acute Condition: Patients diagnosed with non-ST elevation myocardial infarction (non-ST MI).
- •Treatment: Patients who received either invasive treatment (including coronary angiography and revascularization) or conservative (pharmacological) treatment for non-ST MI.
- •Consent: Patients who have provided informed consent or are part of a retrospective study where consent is waived.
Exclusion Criteria
- •Age: Patients younger than 18 years.
- •Non-cancer diagnoses: Patients without a cancer diagnosis.
- •ST-Elevation Myocardial Infarction: Patients with ST elevation myocardial infarction (STEMI) instead of non-ST elevation myocardial infarction (NSTEMI).
- •Pre-existing severe comorbidities: Patients with severe or terminal comorbidities (e.g., end-stage liver disease, end-stage renal disease, or severe cognitive impairment) that would confound the outcomes.
- •Incomplete medical records: Patients with missing data on relevant clinical variables (e.g., GRACE score, treatment received, or mortality data).
- •Pregnancy: Pregnant patients, as their conditions may complicate the interpretation of results.
- •Inability to provide informed consent: Patients unable to provide informed consent (if applicable).
Outcomes
Primary Outcomes
hospital mortality
Time Frame: From the date of hospital admission for NSTEMI until the occurrence of mortality, cardiovascular events, or hospital discharge, assessed up to 30 days.
Hospital mortality rate in cancer patients with non-ST elevation myocardial infarction, comparing invasive and conservative treatment strategies
Secondary Outcomes
- Length of hospital stay:(From the date of hospital admission for NSTEMI until the occurrence of mortality, cardiovascular events, or hospital discharge, assessed up to 100 days.)
- Re-hospitalization rate(The time frame for assessing re-hospitalization is from the date of hospital discharge to 100 days post-discharge)
Investigators
Arif Timuroğlu, MD
Principal Investigator
Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital